Company
Venatorx Pharmaceuticals
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
Venatorx Pharmaceuticals is an AMR Action Fund portfolio company that in August 2025 entered into an exclusive license agreement with Basilea Pharmaceutica Ltd, through which Basilea acquired the global rights to ceftibuten-ledaborbactam etzadroxil, a clinical phase 3-ready oral beta-lactam/beta-lactamase inhibitor combination for the potential treatment of complicated urinary tract infections.
Loading relationship preview